Answers are grounded in this paper and cite their sources.
Sir—Since the publication of our manuscript, “Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor antagonists” [1], we have learned that we inadvertently included foreign adverse event reports in our calculations. We regret this error. We also have been informed that Centocor has modified its method of calculating the total number of patients treated with infliximab (Remicade) in the United States, reducing slightly the estimate for the period of the report, from 233,000 patients to 197,000 patients. On the basis of these data, the rates of tuberculosis (TB) due to infliximab and etanercept use in the United States are 54 and 28 cases per 100,000 treated patients, respectively (P < .0001, by Poisson analysis [2]). Histoplasmosis, coccidioidomycosis, and listeriosis also occurred significantly more often with infliximab use. The corrected analysis appears in table 1. Granulomatous infections in US patients treated with infliximab or etanercept. A major conclusion of our study [1] was that the risk of reactivation of TB was greater with infliximab than with etanercept. We postulated that these drugs had differential effects on preexisting granulomas that were based on differences in their mechanisms of action. Other conditions that impair mycobacterial immunity also increase the risk of disseminated or extrapulmonary disease and shorten the time to onset. Unlike incidence rates, these parameters are not readily compromised by incomplete reporting. We therefore sought to validate our analysis by examining time to onset of tuberculosis (TB) and extent of dissemination with use of the most recent data set released by the US Food and Drug Administration. This analysis was not restricted to cases reported in the United States. Extrapulmonary disease was reported in 114 (26%) of 441 infliximab-associated cases, compared with 4 (10%) of 42 cases for etanercept (P = .017 by Poisson analysis). Meningeal disease was reported in 76 cases (17%), compared with 3 cases of disseminated disease (7%) (P = .07). Among patients receiving infliximab, 44% of TB cases occurred within the first 90 days of therapy, compared with 10% among patients receiving etanercept (P < .001). Country of origin and year of reporting did not affect this relationship. For example, 55% of infliximab-associated TB cases occurred within the first 90 days of therapy when the analysis was restricted to US cases occurring through the third quarter of 2002, compared with 11% of etanercept-associated TB cases. The cumulative proportion of TB cases in relation to duration of anti-TNF therapy is shown in figure 1. The linearity of the etanercept curve is consistent with the occurrence of TB as a random event caused by acquisition of a new infection. In contrast, the clustering of cases in patients shortly after starting infliximab therapy is consistent with an etiology of reactivation, with the inflection of the slope after day 90 of therapy indicating a shift to new infection. On the basis of these observations, the rate of reactivation of TB during the first 90 days of treatment with infliximab was 95 cases per 100,000 person-years, compared with 11 cases per 100,000 person-years for etanercept. The overall TB incidence in the United States (reflecting both reactivation and progression of new infection) at the time of this study was 5.8 cases per 100,000 person-years [3]. Thus, despite the inherent shortcomings of postlicensing surveillance data, we believe that our conclusion—namely, that the risk of reactivation of TB is greater with infliximab therapy than with etanercept therapy—is correct. Cumulative proportion of tuberculosis (TB) cases in relation to start of anti-TNF treatment. Each symbol represents a case reported to the US Food and Drug Administration Adverse Event Reporting System from January 1998 through March 2003. The 2 curves differed by Kaplan-Meier analysis (P = .00028). The inflection in the curve at 90 days of infliximab therapy is consistent with a shift in etiology at that time from reactivation of disease to rapid progression of new infection. Conflict of interest. R.S.W. has served as a consultant for Amgen and is the recipient of a research grant from Wyeth. M.B. and J.W. are former employees of Zynx Health, a subsidiary of the Cerner Corporation. Zynx Health provides consulting services to biotechnology and pharmaceutical companies, including Amgen, which provided grant support for the original study [1]. D.B.: No conflict.
No takes yet. Share an insight, caveat, or question.
Wallis et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: